Pharmaceutical

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

By

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

By

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

By

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

Five things for pharma marketers to know: Thursday, January 22

Five things for pharma marketers to know: Thursday, January 22

By

Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.

Novartis psoriasis drug approval could upend market

Novartis psoriasis drug approval could upend market

By

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

Nurse practitioner workforce has just about doubled

Marketers may want to dust off plans to create NP-centric materials.

Sandoz gets ready to make the biosimilar case with oncologists

Sandoz gets ready to make the biosimilar case with oncologists

By

Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

By

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

Five things for pharma marketers to know: Friday, January 16

Five things for pharma marketers to know: Friday, January 16

By By

CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.

BI weighs sale of generic business

Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.

Abandonment rates indicate room in the anti-TNF market

Abandonment rates indicate room in the anti-TNF market

By

Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

By

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

Five things for pharma marketers to know: Wednesday, January 14

Five things for pharma marketers to know: Wednesday, January 14

By By

Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.

Roche's scuttled cholesterol drug may work

Clinical trials indicate the CTEP works for specific genetic profiles.

Five things for pharma marketers to know: Tuesday, January 13

Five things for pharma marketers to know: Tuesday, January 13

By By

Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.

Pfizer challenges Novartis OTC ad claims

Pfizer challenges Novartis OTC ad claims

By

Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'

NFL players promote Healthcare.gov

HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Five things for pharma marketers to know: Monday, January 12

Five things for pharma marketers to know: Monday, January 12

By By

BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.

Alkermes mid-stage antipsychotic stays on track

A Phase-II study showed the schizophrenia drug performed as well as, but without the weight gain associated with, an older treatment.

AbbVie female health drug's success hinges on safety

AbbVie female health drug's success hinges on safety

By

AbbVie announced positive interim Phase-III results Thursday for its endometriosis drug elagolix, but one analyst says its commercial impact is likely linked to its effect on patients' bone mineral density.

Five things for pharma marketers to  know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

By By By

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Novartis to leverage DNA-editing tool for immunotherapy

The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.

Five things for pharma marketers to know Wednesday, January 7

Five things for pharma marketers to know Wednesday, January 7

By

India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.

Patients lie on EMRs

Clemson University researchers found that patients are not all that honest with healthcare providers.


Email Newsletters